Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xuanfei Baidu Granule for Acute Exacerbation of COPD
NCT06134063Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Randomised, double-blind trial of Xuanfei Baidu in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: Treatment failure rate at 21 days. Status: unknown.
02
Drugs
Xuanfei Baidu
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06134063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06134063.